The Dragon PLC Trial (DRAGON-PLC)
Public ClinicalTrials.gov record NCT06914648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The DRAGON PLC Trial - An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) With PVE Alone in Primary Liver Cancers.
Study identification
- NCT ID
- NCT06914648
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 358 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2025
- Primary completion
- Nov 14, 2032
- Completion
- Nov 14, 2032
- Last update posted
- May 14, 2025
2025 – 2032
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale School of Medicine Hospital | New Haven | Connecticut | 06510 | Not yet recruiting |
| Rush University Medical Center | Chicago | Illinois | 60612 | Not yet recruiting |
| Mayo Clinic | Rochester | Minnesota | 55905 | Not yet recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Not yet recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
Recently updated Cholangiocarcinoma trials
Other public records listing Cholangiocarcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07738939: IKS04 Regimen in Advanced Solid Tumors That Express CA242 Not yet recruiting
- NCT06910670: Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid Recruiting
- NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma Active, not recruiting
- NCT07673341: [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma Not yet recruiting
- NCT07486713: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Recruiting
- NCT06503146: 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06914648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06914648 live on ClinicalTrials.gov.